Phase 2B Efficacy and Safety of XEN1101, a Novel Potassium Channel Modulator, In Adults with Focal Epilepsy (X-TOLE)

被引：0

作者：

French, Jacqueline ^{[1
]}

Porter, Roger ^{[2
]}

Perucca, Emilio ^{[3
]}

Brodie, Martin ^{[4
]}

Rogawski, Michael A. ^{[5
]}

Pimstone, Simon ^{[6
]}

Aycardi, Ernesto ^{[6
]}

Harden, Cynthia ^{[6
]}

Xu, Yi ^{[6
]}

Rosenblut, Constanza Luzon ^{[6
]}

Kenney, Christopher ^{[6
]}

Beatch, Greg ^{[6
]}

机构：

[1] New York Univ, Comprehens Epilepsy Ctr, New York, NY USA

[2] Univ Penn, Philadelphia, PA USA

[3] Monash Univ, Melbourne, Vic, Australia

[4] Western Infirm & Associated Hosp, Univ Dept Med & Therapeut, Glasgow, Lanark, Scotland

[5] Univ Calif Davis, Sch Med, Sacramento, CA USA

[6] Xenon Pharmaceut, Vancouver, BC, Canada

来源：

NEUROTHERAPEUTICS | 2022年 / 19卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：1427 / 1427

页数：1

共 50 条

[1] Phase 2b Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal onset seizures (X-TOLE)
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M.
Pimstone, S.
Aycardi, E.
Harden, C.
Xu, Y.
Rosenblut, C. Luzon
Kenney, C.
Beatch, G.
EPILEPSIA, 2022, 63 : 117 - 118
[2] Rapid onset of efficacy of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: Results from a phase 2b study (X-TOLE)
Kenney, C.
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M.
Harden, C.
Rosenblut, C. Luzon
Qian, J.
Leung, J.
Beatch, G.
EPILEPSIA, 2022, 63 : 136 - 136
[3] The Impact of Disease Severity on Efficacy from a Phase 2b Study of XEN1101, A Novel Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)
Kenney, Christopher
French, Jacqueline
Porter, Roger
Perucca, Emilio
Brodie, Martin
Rogawski, Michael A.
Harden, Cynthia
Qian, Jenny
Beatch, Greg
NEUROTHERAPEUTICS, 2022, 19 (04) : 1427 - 1428
[4] The impact of disease severity on efficacy from a Phase 2b study of XEN1101, a novel potassium channel opener, in adults with focal epilepsy (X-TOLE)
Kenney, C.
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M.
Harden, C.
Rosenblut, C. Luzon
Qian, J.
Leung, J.
Beatch, G.
EPILEPSIA, 2022, 63 : 136 - 136
[5] XEN1101, a novel potassium channel modulator: interim data from an ongoing, long-term, open-label extension of a phase 2b study (X-TOLE) in adults with focal epilepsy
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M. A.
Harden, C.
Qian, J.
Luzon-Rosenblut, C.
Kenney, C.
Beatch, G. N.
EPILEPSIA, 2023, 64 : 275 - 276
[6] Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy
French, Jacqueline A.
Porter, Roger J.
Perucca, Emilio
Brodie, Martin J.
Rogawski, Michael A.
Pimstone, Simon
Aycardi, Ernesto
Harden, Cynthia
Qian, Jenny
Luzon Rosenblut, Constanza
Kenney, Christopher
Beatch, Gregory N.
JAMA NEUROLOGY, 2023, 80 (11) : 1145 - 1154
[7] XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy
French, Jacqueline
Porter, Roger
Perucca, Emilio
Brodie, Martin
Rogawski, Michael
Harden, Cynthia
Qian, Jenny
Luzon-Rosenblut, Constanza
Kenney, Christopher
Beatch, Gregory
NEUROLOGY, 2023, 100 (17)
[8] XEN1101, a novel, potent potassium channel modulator: Interim data from an ongoing, long-term, open-label extension of a Phase 2b study (X-TOLE) in adults with focal onset seizures (FOS)
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M. A.
Harden, C.
Qian, J.
Rosenblut, C. Luzon
Kenney, C.
Beatch, G. N.
EPILEPSIA, 2024, 65 : 184 - 184
[9] Efficacy and Safety of XEN1101,aNovelPotassiumChannelOpener,in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial (vol 80, pg 1145, 2023)
不详
JAMA NEUROLOGY, 2024, 81 (02) : 200 - 200
[10] XEN1101, a novel potassium channel opener: hope or hype for adults with focal seizure
Fareed, Areeba
Sohail, Afra
Siddiqui, Wajeeha
Asif, Muhammad Iqbal
Ahmed, Tagwa Kalool Fadlalla
ANNALS OF MEDICINE AND SURGERY, 2024, 86 (05): : 2417 - 2419

← 1 2 3 4 5 →